BLACK DIAMOND THERAPEUTICS I (BDTX) Institutional Selling Activity
Several institutional investors tracked by InsiderSet reduced exposure to BLACK DIAMOND THERAPEUTICS I (BDTX) during the quarter ended March 31, 2026 based on sequential SEC Form 13F filings.
Institutional selling activity may reflect profit-taking, sector rotation, portfolio rebalancing, or changing conviction levels among major investment firms. InsiderSet tracks quarter-over-quarter holding reductions, full exits, estimated value changes, and historical selling activity using publicly disclosed SEC filing data.
No data available.
Frequently asked questions about BDTX activity
Which institutional owners are buying BDTX?
Institutional owners buying BDTX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in BDTX activity?
"Buy" means an investor increased their reported position in BDTX compared to the prior reporting period. This reflects growing exposure to BLACK DIAMOND THERAPEUTICS I (BDTX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in BDTX increasing?
Institutional interest in BDTX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.